The Latest SPAC News and Rumors: January 3, 2023

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Royalty Management expands investment in Ferrox Holdings to over 10% equity ownership and ZyVersa Therapeutics adds two leading nephrologists to its Renal Scientific Advisory Board

American Acquisition Opportunity’s Target, Royalty Management, Expands Investment in Ferrox Holdings to Over 10% Equity Ownership

American Acquisition Opportunity Inc.’s (NASDAQ:AMAO) merger target company, Royalty Management Corporation (RMC), a sustainably driven, cash flow-oriented, royalty investment and development company, announced today that it has expanded its stake in one of its portfolio holdings, Ferrox Holdings Ltd. (“Ferrox”) through a common stock issuance; issuing stock in Royalty Management Corporation for approximately 10% of Ferrox. The common stock issued by Royalty Management Corporation for its investment in Ferrox is valued at $10.00 per share equivalent of American Acquisition Opportunity’s stock post the pending merger.

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases, announces that two leading nephrologists, Daniel Cattran and Fernando Fervenza, have joined ZyVersa’s Renal Scientific Advisory Board.